68.1 F
New York
Wednesday, September 23, 2020

Axsome Therapeutics (NASDAQ:AXSM) Forms Bullish Trend on Positive News

Must read

Momo Inc. (NASDAQ:MOMO) Finding Zero Support

Momo Inc. (MOMO) shares are trading at lower $14.69 and the avg recommendation for the stock is Moderate Buy. while the current analyst price...

Apartment Investment and Management Company (NYSE:AIV) on the Path to Ruin

Apartment Investment and Management Company (AIV) shares are trading at lower $33.12 and the avg recommendation for the stock is Moderate Buy. while the...

The Unprecedented Rise of Targa Resources Corp. (NYSE:TRGP)

Targa Resources Corp. (TRGP) shares are trading at lower $14.69 and the avg recommendation for the stock is Moderate Buy. while the current analyst...

Investor Confidence is Falling for Viavi Solutions Inc. (NASDAQ:VIAV)

Viavi Solutions Inc. (VIAV) shares are trading at lower $11.83 and the avg recommendation for the stock is Strong Buy. while the current analyst...

AXSM’s stock has been in the news in recent weeks, having registered two wins and one setback in three clinical trials, which are in the latter stages. Back in March, Axsome Therapeutics Inc’s (NASDAQ:AXSM) product AXS 05 failed to meet the primary endpoint for treatment-resistant depression, but some time later, it was successful when trialed for Alzheimer’s.

Key Developments

On the other hand, AXS 07, meant for treating migraine pain, also managed to successfully complete its Phase 3 clinical trial. AXS 05 is meant for patients who experience different types of agitation in relation to Alzheimer’s and is one of the more promising products at Axsome at this point.

Currently, there are six million Alzheimer’s patients in the United States, and out of those, 70% of the patients suffer from agitation. Hence, the product potentially has a massive market to cater to. Since the late-stage trial has been a success, the company aims to present the data to the United States Food and Drug Administration and get approval for AXS 05. The company is planning to file a new drug application at some point in Q4 2020. However, that is not all. The company is planning to do the same with its migraine pain product AXS 07.

That medicine could also have a huge market in the United States, considering the fact that as many as 40 million people in the country suffer from severe migraines every year. The Axsome stock is currently trading at $91 a share, and in 2019 alone, the stock had rallied by as much as 3600%. Estimates from six analysts suggest that in the next 12 months, the Axsome stock could be in the $115 to $210 per share range.

The two products could both be major successes for the company. However, it should also be noted that if the company does get approval, then it could also become an acquisition target for some of the biggest players in the pharmaceutical industry. The current level of the stock seems attractive all things considered, and it could be worthwhile for investors to keep an eye on the Axsome stock. Sign-Up Below to stay up to date on any breakouts with Axsome or other fast-moving stocks.

Latest article

Urban Outfitters Inc. (NASDAQ:URBN) on the Path to Ruin

Urban Outfitters Inc. (URBN) shares are trading at lower $21.02 and the avg recommendation for the stock is Moderate Buy. while the current analyst...

Is Now the Time to Invest in Dollar Tree Inc. (NASDAQ:DLTR)?

Dollar Tree Inc. (DLTR) shares are trading at lower $85.97 and the avg recommendation for the stock is Moderate Buy. while the current analyst...

Teradyne Inc. (NASDAQ:TER) Stock is Soaring, Here is Why

Teradyne Inc. (TER) shares are trading at higher $76.92 and the avg recommendation for the stock is Moderate Buy. while the current analyst price...

Huntsman Corporation (NYSE:HUN) is Holding Steady

Huntsman Corporation (HUN) shares are trading at lower $22.07 and the avg recommendation for the stock is Moderate Buy. while the current analyst price...

Investor Confidence is Rising for Electronic Arts Inc. (NASDAQ:EA)

Electronic Arts Inc. (EA) shares are trading at higher $128.29 and the avg recommendation for the stock is Moderate Buy. while the current analyst...